Compare Novavax Inc (NVAX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Sanofi SA — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 80.6× Novavax Inc's market cap, and Sanofi SA pays a 5.5% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SNY | |
|---|---|---|
Market Cap | $1.30B | $104.83B |
Sector | Health | Health |
52-Week High | $11.19 | $52.34 |
52-Week Low | $6.22 | $41.33 |
Enterprise Value | $800.50M | $121.32B |
Dividend Yield | — | 5.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
